Skip to main content

Advertisement

SpringerLink
Log in

Complementary and Integrative Medicine in Hematologic Malignancies: Questions and Challenges

  • Integrative Care (C Lammersfeld, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Hematologic malignancies represent 9.7% of all cancers, making them the fourth most common type of cancer in the United States. The aggressive and complex treatments administered in hematologic malignancies result in a high burden of psychological needs. Complementary and integrative medicine (CIM) is becoming one of the options that patients use to address their distress during and after cancer treatments. It is not clear whether appropriate CIM can relieve distress in patients affected by these malignancies. This review covers the potential benefits of CIM as relates to nutrition, nutritional supplements, exercise, circadian rhythm, methods for reducing distress during bone marrow aspiration, massage therapy, and acupuncture, in treating patients with hematological malignancies. This review may provide a framework to enhance patient-doctor dialogue regarding CIM use in hematologic malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute; updated Sept. 12, 2016. http://seer.cancer.gov/csr/1975_2013/. Accessed 23 Dec 2016.

  2. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30(24):3012–9.

    Article  PubMed  Google Scholar 

  4. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Supplement 1):4–10.

    Article  PubMed  Google Scholar 

  5. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535–43.

    Article  CAS  PubMed  Google Scholar 

  6. Bellm L, Epstein J, Rose-Ped A, Martin P, Fuchs H. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8:33–9.

    CAS  PubMed  Google Scholar 

  7. Barata A, Wood WA, Choi SW, Jim HS. Unmet needs for psychosocial care in hematologic malignancies and hematopoietic cell transplant. Curr Hematol Malig Rep. 2016;11(4):280–7.

    Article  PubMed  Google Scholar 

  8. Boyes AW, Clinton-McHarg T, Waller AE, Steele A, D'Este CA, Sanson-Fisher RW. Prevalence and correlates of the unmet supportive care needs of individuals diagnosed with a haematological malignancy. Acta Oncol. 2015;54:507–14.

    Article  PubMed  Google Scholar 

  9. Hall A, Clinton-McHarg T, Waller AE, Steele A, D'Este CA, Sanson-Fisher RW. Factors associated with haematological cancer survivors experiencing a high level of unmet need across multiple items of supportive care: a cross-sectional survey study. Support Care Cancer. 2014;22:2899–909.

    Article  PubMed  Google Scholar 

  10. Linden W, Vodermaier A, MacKenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141:343–51.

    Article  PubMed  Google Scholar 

  11. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psycho-Oncology. 2010;20(1):88–97.

    Article  Google Scholar 

  12. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.

    Article  PubMed  Google Scholar 

  13. Molassiotis A, Margulies A, Fernandez-Ortega P, et al. Complementary and alternative medicine use in patients with haematological malignancies in Europe. Complement Ther Clin Pract. 2005;11(2):105–10.

    Article  PubMed  Google Scholar 

  14. Hensel M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer. 2009;17(1):47–52.

    Article  PubMed  Google Scholar 

  15. D'Arena G, Laurenti L, Coscia M, et al. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leuk Lymphoma. 2014;55(4):841–7.

    Article  PubMed  Google Scholar 

  16. Gan GG, Leong YC, Bee PC, Chin E, et al. Complementary and alternative medicine use in patients with hematological cancers in Malaysia. Support Care Cancer. 2015;23(8):2399–406.

    Article  CAS  PubMed  Google Scholar 

  17. Hierl M, Pfirstinger J, Andreesen R, Holler E, Mayer S, Wolff D, et al. Complementary and alternative medicine: a clinical study in 1,016 hematology/oncology patients. Oncology. 2017; https://doi.org/10.1159/000464248.

  18. •• Rausch Osian S, Leal AD, Allmer C, et al. Widespread use of complementary and alternative medicine (CAM) among non-Hodgkin lymphoma (NHL) survivors. Leuk Lymphoma. 2015;56(2):434–9. In this report of non-Hodgkin lymphoma (NHL) survivors, 89% reported using CIM: 78% took vitamins, 54% used alternative therapies, and 45% used herbal remedies.

    Article  PubMed  Google Scholar 

  19. Mao JJ, Cohen L. Advancing the science of integrative oncology to inform patient-centered care for cancer survivors. J Natl Cancer Inst Monogr. 2014;2014(50):283–4.

    Article  PubMed  Google Scholar 

  20. Rowland JH, O’Mara A. Survivorship care planning: unique opportunity to champion integrative oncology? J Natl Cancer Inst Monogr. 2014;2014(50):285.

    Article  PubMed  PubMed Central  Google Scholar 

  21. •• Frenkel M, Cohen L. Effective communication about the use of complementary and integrative medicine in cancer care. J Altern Complement Med. 2014;20(1):12–8. In this paper the issue of communication about CIM in cancer care is discussed with practical important tips and suggestions for effective communication.

    Article  PubMed  PubMed Central  Google Scholar 

  22. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Expert Report. Washington, DC: AICR, 1997 (update 2007).

  23. Saberi Hosnijeh F, Peeters P, Romieu I, et al. Dietary intakes and risk of lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Nutr Cancer. 2014;66(1):14–28.

    Article  CAS  PubMed  Google Scholar 

  24. Han X, Zheng T, Foss F, et al. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leuk Lymphoma. 2010;51(6):1047–54.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26(35):5684–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. •• Tramsen L, Salzmann-Manrique E, Bochennek K, et al. Lack of effectiveness of neutropenic diet and social restrictions as anti-infective measures in children with acute myeloid leukemia: an analysis of the AML-BFM 2004 trial. J Clin Oncol. 2016;34(23):2776–83. In this study researchers evaluated infectious complications during intensive treatment in 339 children with AML with neutropenic diet compared to fresh fruits and vegetables diet, and concluded that owing to the lack of effectiveness of dietary restrictions, anti-infection policies should be reconsidered.

    Article  PubMed  PubMed Central  Google Scholar 

  27. American Institute of Cancer Research. Foods that fight cancer? http://www.aicr.org/foods-that-fight-cancer/. Accessed 14 Oct 2016.

  28. Hohl RJ. Monoterpenes as regulators of malignant cell proliferation. Adv Exp Med Biol. 1996;401:137–46.

    Article  CAS  PubMed  Google Scholar 

  29. Zaini R, Clench MR, Le Maitre CL. Bioactive chemicals from carrot (Daucus carota) juice extracts for the treatment of leukemia. J Med Food. 2011;14(11):1303–12.

    Article  CAS  PubMed  Google Scholar 

  30. Dahlawi H, Jordan-Mahy N, Clench MR, et al. Bioactive actions of pomegranate fruit extracts on leukemia cell lines in vitro hold promise for new therapeutic agents for leukemia. Nutr Cancer. 2012;64:100–10.

    Article  PubMed  Google Scholar 

  31. Turrini E, Ferruzzi L, Fimognari C. Potential effects of pomegranate polyphenols in cancer prevention and therapy. Oxidative Med Cell Longev. 2015;2015:938475.

    Article  CAS  Google Scholar 

  32. Asmaa MJ, Ali AJ, Farid JM, Azman S. Growth inhibitory effects of crude pomegranate peel extract on chronic myeloid leukemia, K562 cells. Int J Appl Basic Med Res. 2015;5(2):100–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Tattelman E. Health effects of garlic. Am Fam Phys. 2005;72:103–6.

    Google Scholar 

  34. Padilla-Camberos E, Zaitseva G, Padilla C, Puebla AM. Antitumoral activity of allicin in murine lymphoma L5178Y. Asian Pac J Cancer Prev. 2010;11(5):1241–4.

    PubMed  Google Scholar 

  35. Goya L, Martín MÁ, Sarriá B, et al. Effect of cocoa and its flavonoids on biomarkers of inflammation: studies of cell culture, animals and humans. Nutrients. 2016;8(4):212.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Preza AM, Jaramillo ME, Puebla AM, Mateos JC, Hernández R, Lugo E. Antitumor activity against murine lymphoma L5178Y model of proteins from cacao (Theobroma cacao L.) seeds in relation with in vitro antioxidant activity. BMC Complement Altern Med. 2010;10:61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Yang L, Dong J, Jiang S, et al. Red and processed meat consumption increases risk for non-Hodgkin lymphoma: a PRISMA-compliant meta-analysis of observational studies. Medicine (Baltimore). 2015;94(45):e1729.

    Article  CAS  Google Scholar 

  38. Caini S, Masala G, Gnagnarella P, et al. Food of animal origin and risk of non-Hodgkin lymphoma and multiple myeloma: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2016;100:16–24.

    Article  PubMed  Google Scholar 

  39. Epstein MM, Chang ET, Zhang Y, et al. Dietary pattern and risk of Hodgkin lymphoma in a population-based case-control study. Am J Epidemiol. 2015;182(5):405–16.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Schernhammer ES, Bertrand KA, Birmann BM, Sampson L, Willett WC, Feskanich D. Consumption of artificial sweetener- and sugar-containing soda and risk of lymphoma and leukemia in men and women. Am J Clin Nutr. 2012;96(6):1419–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Vergnaud AC, Romaguera D, Peeters PH, et al. Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe: results from the European Prospective Investigation into Nutrition and Cancer cohort study. Am J Clin Nutr. 2013;97(5):1107–20.

    Article  CAS  PubMed  Google Scholar 

  42. Bertolini F, Fusetti L, Rabascio C, et al. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin’s lymphoma. Leukemia. 2000;14(8):1477–82.

    Article  CAS  PubMed  Google Scholar 

  43. Lee YK, Bone ND, Strege AK, et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004;104(3):788–94.

    Article  CAS  PubMed  Google Scholar 

  44. Nakazato T, Ito K, Ikeda Y, et al. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res. 2005;11(16):6040–9.

    Article  CAS  PubMed  Google Scholar 

  45. Noda C, He J, Takano T, et al. Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells. Biochem Biophys Res Commun. 2007;362(4):951–7.

    Article  CAS  PubMed  Google Scholar 

  46. Zhang M, Zhao X, Zhang X, et al. Possible protective effect of green tea intake on risk of adult leukaemia. Br J Cancer. 2008;98(1):168–70.

    Article  CAS  PubMed  Google Scholar 

  47. Kuo YC, Yu CL, Liu CY, et al. A population-based, case control study of green tea consumption and leukemia risk in southwestern Taiwan. Cancer Causes Control. 2009;20(1):57–65.

    Article  PubMed  Google Scholar 

  48. Frankenfeld CL, Cerhan JR, Cozen W, et al. Dietary flavonoid intake and non-Hodgkin lymphoma risk. Am J Clin Nutr. 2008;87(5):1439–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Naganuma T, Kuriyama S, Kakizaki M, et al. Green tea consumption and hematologic malignancies in Japan: the Ohsaki study. Am J Epidemiol. 2009;170(6):730–8.

    Article  PubMed  Google Scholar 

  50. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009;113(23):5927–37.

    Article  CAS  PubMed  Google Scholar 

  51. Nagy LI, Fehér LZ, Szebeni GJ, et al. Curcumin and its analogue induce apoptosis in leukemia cells and have additive effects with bortezomib in cellular and xenograft models. Biomed Res Int. 2015;2015:968981.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Kelkel M, Jacob C, Dicato M, et al. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules. 2010;15(10):7035–74.

    Article  CAS  PubMed  Google Scholar 

  53. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. B-cell disorders and curcumin. Integr Cancer Ther. 2017;16(3):255–257.

  54. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol. 2012;87(5):455–60.

    Article  CAS  PubMed  Google Scholar 

  55. Bassiouny AR, Atteya MA, El-Rashidy FH, et al. Curcumin and EGCG suppress apurinic/apyrimidinic endonuclease 1 and induce complete remission in B-cell non-Hodgkin’s lymphoma patients. Funct Foods Health Dis. 2011;12:525–44.

    Google Scholar 

  56. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008;6(6):1059–70.

    Article  CAS  PubMed  Google Scholar 

  57. Hagag AA, AbdElaal AM, Elfaragy MS, Hassan SM, Elzamarany EA. Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia. Infect Dis Drug Targets. 2015;15(1):64–71.

    Article  CAS  Google Scholar 

  58. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol. 2008;26(4):665–73.

    Article  CAS  PubMed  Google Scholar 

  59. •• Frenkel M, Abrams D, Ladas E, et al. Integrating dietary supplements into cancer care. Integr Cancer Ther. 2013;12:369–84. A landmark paper on the use of selected nutritional supplements in cancer care with practical discussion points.

    Article  CAS  PubMed  Google Scholar 

  60. Giordanoa M, Crocib DO, Rabinovich GA. Galectins in hematological malignancies. Curr Opin Hematol. 2013;20:327–35.

    Article  CAS  Google Scholar 

  61. Ramachandran C, Wilk BJ, Hotchkiss A, et al. Activation of human T-helper/inducer cell, T-cytotoxic Cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med. 2011;11:59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301–4.

    Article  CAS  PubMed  Google Scholar 

  63. •• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(Issue 6264):1084–9. In this study oral administration of Bifidobacterium improved tumor control to the same degree as programmed death-ligand 1 antibody (immune checkpoint blockade) therapy. The authors concluded that manipulating the microbiota may modulate cancer immunotherapy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Iyer C, Kosters A, Sethi G, et al. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell Microbiol. 2008;10(7):1442–52.

    Article  CAS  PubMed  Google Scholar 

  65. Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent Clostridium difficile infection. J Crohns Colitis. 2014;8:252–3.

    Article  PubMed  Google Scholar 

  66. Gerbitz A, Schultz M, Wilke A, Linde H-J, Schölmerich J, Andreesen R, et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood. 2004;103:4365–7.

    Article  CAS  PubMed  Google Scholar 

  67. Wang B, Huang Q, Zhang W, Li N, Li J. Lactobacillus plantarum prevents bacterial translocation in rats following ischemia and reperfusion injury. Dig Dis Sci. 2011;56(11):3187–94.

    Article  PubMed  Google Scholar 

  68. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 1996;111(2):334–44.

    Article  CAS  PubMed  Google Scholar 

  69. Zareie M, Johnson-Henry K, Jury J, Yang PC, Ngan BY, DM MK, et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut. 2006;55(11):1553–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. •• Ladas EJ, Bhatia M, Chen L, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 2015; https://doi.org/10.1038/bmt.2015.275. In this study researchers evaluated the safety of probiotics in children and adolescents undergoing allogeneic hematopoietic cell transplantation and found no adverse events related to the probiotics. The researchers concluded that their study provides preliminary evidence that administration of probiotics is safe and feasible in children and adolescents undergoing hematopoietic cell transplantation.

  71. Cooley K, Szczurko O, Perri D, et al. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. PLoS One. 2009;4(8):e6628.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2013;12(4):312–22.

    Article  CAS  PubMed  Google Scholar 

  73. Jayaprakasam B, Zhang Y, Seeram NP, et al. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 2003;74(1):125–32.

    Article  CAS  PubMed  Google Scholar 

  74. McKenna MK, Gachuki BW, Alhakeem SS, et al. Anti-cancer activity of withaferin A in B-cell lymphoma. Cancer Biol Ther. 2015;16(7):1088–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Turrini E, Calcabrini C, Sestili P, et al. Withania somnifera induces cytotoxic and cytostatic effects on human T leukemia cells. Toxins (Basel). 2016;8(5):147. https://doi.org/10.3390/toxins8050147.

    Article  CAS  Google Scholar 

  76. Bell GA, Kantor ED, Lampe JW, et al. Intake of long-chain ω-3 fatty acids from diet and supplements in relation to mortality. Am J Epidemiol. 2014;179(6):710–20.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Alfano CM, Imayama I, Neuhouser ML, Kiecolt-Glaser JK, Smith AW, Meeske K, et al. Fatigue, inflammation, and ω-3 and ω-6 fatty acid intake among breast cancer survivors. J Clin Oncol. 2012;30(12):1280–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Betiati Dda S, de Oliveira PF, Camargo Cde Q, et al. Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms. Rev Bras Hematol Hemoter. 2013;35(2):119–25.

    PubMed  Google Scholar 

  79. Ogilvie GK, Fettman MJ, Mallinckrodt CH, Walton JA, Hansen RA, Devenport DJ, et al. Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. Cancer. 2000;88(8):1916–28.

    Article  CAS  PubMed  Google Scholar 

  80. Johansson AS, Norén-Nystrom U, Larefalk A, et al. Fish oil delays lymphoma progression in the TLL mouse. Leuk Lymphoma. 2010;51(11):2092–7.

    Article  CAS  PubMed  Google Scholar 

  81. Takatsuka H, Takemoto Y, Iwata N, et al. Oral eicosapentaenoic acid for complications of bone marrow transplantation. Bone Marrow Transplant. 2001;28(8):769–74.

    Article  CAS  PubMed  Google Scholar 

  82. •• Elbarbary NS, Ismail EA, Farahat RK, et al. ω-3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: a randomized placebo-controlled study. Nutrition. 2016;32(1):41–7. In this randomized placebo-controlled clinical trial involving 70 patients with acute lymphoblastic leukemia (ALL) who were in the maintenance phase, researchers evaluated the effect of ω-3 on methotrexate hepatotoxicity. The researchers concluded that on the base of their study, ω-3 fatty acids ameliorated methotrexate -induced hepatotoxicity and could be safely used during the maintenance phase of ALL.

    Article  CAS  PubMed  Google Scholar 

  83. Loprinzi PD, Cardinal BJ, Winters-Stone K, Smit E, Loprinzi CL. Physical activity and the risk of breast cancer recurrence: a literature review. Oncol Nurs Forum. 2012;39:269–74.

    Article  PubMed  Google Scholar 

  84. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24:3527–34.

    Article  PubMed  Google Scholar 

  85. Mishra S, Scherer R, Geigle P, et al. Exercise interventions on health-related quality of life for cancer survivors (review). Cochrane Database Syst Rev. 2012;8:CD007566.

    Google Scholar 

  86. Eckert R, Huberty J, Gowin K, Mesa R, Marks L, et al. Physical activity as a nonpharmacological symptom management approach in myeloproliferative neoplasms: recommendations for future research. Integr Cancer Ther. 2016; https://doi.org/10.1177/1534735416661417.

  87. Santiago-Fernández O, Osorio FG, López-Otín C. Proteostasis alterations in myeloproliferative neoplasms: oncogenic relevance and therapeutic opportunities. Exp Hematol. 2016;44:574–7.

    Article  PubMed  CAS  Google Scholar 

  88. Kruijsen-Jaarsma M, Révész D, Bierings MB, et al. Effects of exercise on immune function in patients with cancer: a systematic review. Exerc Immunol Rev. 2013;19:120–43.

    PubMed  Google Scholar 

  89. Baumann FT, Zimmer P, Finkenberg K, Hallek M, Bloch W, Elter T. Influence of endurance exercise on the risk of pneumonia and fever in leukemia and lymphoma patients undergoing high dose chemotherapy: a pilot study. J Sports Sci Med. 2012;11:638–42.

    PubMed  PubMed Central  Google Scholar 

  90. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of randomized controlled trials. BMJ. 2012;344:e70.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Mishra SI, Scherer RW, Snyder C, et al. Are exercise programs effective for improving health-related quality of life among cancer survivors? A systematic review and meta-analysis. Oncol Nurs Forum. 2014;41:E326–42.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-Reich A. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer. 2004;100:2253–60.

    Article  PubMed  Google Scholar 

  93. Courneya KS, Sellar CM, Stevinson C, et al. Moderator effects in a randomized controlled trial of exercise training in lymphoma patients. Cancer Epidemiol Biomark Prev. 2009;18:2600–7.

    Article  Google Scholar 

  94. Courneya KS, Sellar CM, Stevinson C, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol. 2009;27:4605–12.

    Article  PubMed  Google Scholar 

  95. Courneya KS, Sellar CM, Trinh L, et al. A randomized trial of aerobic exercise and sleep quality in lymphoma patients receiving chemotherapy or no treatments. Cancer Epidemiol Biomark Prev. 2012;21:887–94.

    Article  Google Scholar 

  96. Elter T, Stipanov M, Heuser E, et al. Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma? Int J Hematol. 2009;90:199–204.

    Article  CAS  PubMed  Google Scholar 

  97. Smith A, Roman E, Howell D, et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol. 2010;148:739–53.

    Article  PubMed  Google Scholar 

  98. Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/ small lymphocytic lymphoma: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:41–51.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Zhu Y, Zheng T. Clock-cancer connection in non-Hodgkin’s lymphoma. Med Hypotheses. 2008;70:788–92.

    Article  PubMed  Google Scholar 

  100. Rana S, Munawar M, Shahid A, et al. Deregulated expression of circadian clock and clock-controlled cell cycle genes in chronic lymphocytic leukemia. Mol Biol Rep. 2014;41:95–103.

    Article  CAS  PubMed  Google Scholar 

  101. Costas L, Benavente Y, Olmedo-Requena R, et al. Night shift work and chronic lymphocytic leukemia in the MCC-Spain case-control study. Int J Cancer. 2016;139(9):1994–2000.

    Article  CAS  PubMed  Google Scholar 

  102. Sánchez-Hidalgo M, Lee M, de la Lastra CA, et al. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J Pineal Res. 2012;53(4):366–73.

    Article  PubMed  CAS  Google Scholar 

  103. Hughes AM, Armstrong BK, Vajdic CM, et al. Sun exposure may protect against non-Hodgkin’s lymphoma: a case control study. Int J Cancer. 2004;112:865–71.

    Article  CAS  PubMed  Google Scholar 

  104. Smedby KE, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst. 2005;97:199–209.

    Article  PubMed  Google Scholar 

  105. Petridou ET, Dikalioti SK, Skalkidou A, et al. Sun exposure, birth weight, and childhood lymphomas: a case control study in Greece. Cancer Causes Control. 2007;18(9):1031–7.

    Article  PubMed  Google Scholar 

  106. Armstrong BK, Kricker A. Sun exposure and non-Hodgkin lymphoma. Cancer Epidemiol Biomark Prev. 2007;16(3):396–400.

    Article  CAS  Google Scholar 

  107. Redd WH, Valdimarsdottir H, Wu LM, et al. Systematic light exposure in the treatment of cancer-related fatigue: a preliminary study. Psychooncology. 2014;23(12):1431–4.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Ancoli-Israel S, Rissling M, Neikrug A, et al. Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer. 2012;20(6):1211–9.

    Article  PubMed  Google Scholar 

  109. Portnow J, Lim C, Grossman SA. Assessment of pain caused by invasive procedures in cancer patients. J Natl Compr Cancer Netw. 2003;1:435e439.

    Google Scholar 

  110. Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S. Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Manag. 2003;26:860–6.

    Article  Google Scholar 

  111. Lechtzin N, Busse AM, Smith MT, et al. A randomized trial of nature scenery and sounds versus urban scenery and sounds to reduce pain in adults undergoing bone marrow aspirate and biopsy. J Altern Complement Med. 2010;16(9):965–72.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst. 2007;99(17):1304–12.

    Article  PubMed  Google Scholar 

  113. Bao T, Ye X, Skinner J, et al. The analgesic effect of magnetic acupressure in cancer patients undergoing bone marrow aspiration and biopsy: a randomized, blinded, controlled trial. J Pain Symptom Manag. 2011;41(6):995–1002.

    Article  Google Scholar 

  114. Çelebioğlu A, Gürol A, Yildirim ZK, et al. Effects of massage therapy on pain and anxiety arising from intrathecal therapy or bone marrow aspiration in children with cancer. Int J Nurs Pract. 2015;21(6):797–804.

    Article  PubMed  Google Scholar 

  115. Davies E, Campbell S, Fullwood A, et al. The introduction of a holistic massage service in a combined paediatric and adult BMT unit. Bone Marrow Transplant. 2008;41(4):407–8.

    Article  CAS  PubMed  Google Scholar 

  116. Smith MC, Reeder F, Daniel L, Baramee J, Hagman J. Outcomes of touch therapies during bone marrow transplant. Altern Ther Health Med. 2003;9(1):40–9.

    PubMed  Google Scholar 

  117. Mehling WE, Lown EA, Dvorak CC, et al. Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial. Evid Based Complement Alternat Med. 2012;2012:450150. https://doi.org/10.1155/2012/450150.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Russell NC, Sumler SS, Beinhorn CM, Frenkel MA. Role of massage therapy in cancer care. J Altern Complement Med. 2008;14(2):209–14.

    Article  PubMed  Google Scholar 

  119. Lee SH, Kim JY, Yeo S, et al. Meta-analysis of massage therapy on cancer pain. Integr Cancer Ther. 2015;14:297–304.

    Article  PubMed  Google Scholar 

  120. Kutner JS, Smith MC, Corbin L, et al. Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med. 2008;149:369–79.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Post-White J, Kinney ME, Savik K, Gau JB, Wilcox C, et al. Therapeutic massage and healing touch improve symptoms in cancer. Integr Cancer Ther. 2003;2:332–44.

    Article  PubMed  Google Scholar 

  122. Hernandez-Reif M, Ironson G, Field T, Hurley J, Katz G, et al. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. J Psychosom Res. 2004;57:45–52.

    Article  PubMed  Google Scholar 

  123. Taylor AG, Snyder AE, Anderson JG, et al. Gentle massage improves disease and treatment related symptoms in patients with acute myelogenous leukemia. J Clin Trials. 2014;4. https://doi.org/10.4172/2167-0870.1000161.

  124. Fu H, Chen B, Hong S, Guo Y. Acupuncture therapy for the treatment of myelosuppression after chemotherapy: a literature review over the past 10 years. J Acupunct Meridian Stud. 2015;8(3):122–6.

    Article  PubMed  Google Scholar 

  125. Lu W, Rosenthal DS. Recent advances in oncology acupuncture and safety considerations in practice. Curr Treat Options in Oncol. 2010;11(3–4):141–6.

    Article  Google Scholar 

  126. Chien TJ, Liu CY, Hsu CH. Integrating acupuncture into cancer care. J Tradit Complement Med. 2013;3(4):234–9.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Lu W, Matulonis UA, Doherty-Gilman A, et al. Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med. 2009;15(7):745–53.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Pais I, Correia N, Pimentel I, et al. Effects of acupuncture on leucopenia, neutropenia, NK, and B cells in cancer patients: a randomized pilot study. Evid Based Complement Alternat Med. 2014;2014:217397.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Wong R, Sagar S. Acupuncture treatment for chemotherapy induced peripheral neuropathy—a case series. Acupunct Med. 2006;24:87–91.

    Article  PubMed  Google Scholar 

  130. Donald GK, Tobin I, Stringer J. Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Acupunct Med. 2011;29(3):230–3.

    Article  PubMed  Google Scholar 

  131. Hsieh YL, Chou LW, Hong SF, et al. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study. Acupunct Med. 2016;34(5):398–405.

    Article  PubMed  Google Scholar 

  132. Wong R, Major P, Sagar S. Phase 2 study of acupuncture-like transcutaneous nerve stimulation for chemotherapy-induced peripheral neuropathy. Integr Cancer Ther. 2016;15(2):153–64.

    Article  CAS  PubMed  Google Scholar 

  133. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593–9.

    Article  CAS  PubMed  Google Scholar 

  134. Bao T, Zhang R, Badros A, Lao L. Acupuncture treatment for bortezomib-induced peripheral neuropathy: a case report. Pain Res Treat. 2011;2011:920807.

    PubMed  PubMed Central  Google Scholar 

  135. Bao T, Lao L, Medeiros M, Zhang R, Dorsey SG, Badros A. Improvement of painful bortezomib-induced peripheral neuropathy following acupuncture treatment in a case series of multiple myeloma patients. Med Acupunct. 2012;24:181–7.

    Article  PubMed Central  Google Scholar 

  136. •• Bao T, Goloubeva O, Pelser C, et al. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther. 2014;13(5):396–404. In this study researchers studied the value of acupuncture in addressing bortezomib-induced peripheral neuropathy. Researchers concluded that acupuncture appears to be safe and feasible and produces subjective improvements in patients’ symptoms.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Garcia MK, Cohen L, Guo Y, et al. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014;7:41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Prof. Martin Ellis MD, director of hematology in Meir Medical Center, Kfar Saba Israel, for reviewing the manuscript and making very helpful comments to increase the quality of this manuscript.

Author information

Authors and Affiliations

  1. Department of Family Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX, USA

    Moshe Frenkel

  2. Integrative Medicine Program, Institute of Oncology, Meir Medical Center, Kfar Saba, Israel

    Moshe Frenkel

  3. Hashoftim 1 B, 30900, Zichron Yaacov, Israel

    Moshe Frenkel

  4. Department of Anesthesia and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kenneth Sapire

Authors
  1. Moshe Frenkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Sapire
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Moshe Frenkel.

Ethics declarations

Conflict of Interest

Moshe Frenkel and Kenneth Sapire declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Integrative Care

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frenkel, M., Sapire, K. Complementary and Integrative Medicine in Hematologic Malignancies: Questions and Challenges. Curr Oncol Rep 19, 79 (2017). https://doi.org/10.1007/s11912-017-0635-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-017-0635-0

Keywords

Search

Navigation